Skip to main content

Table 2 Virologic failures with RPV + bDRV

From: Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study)

Patient

Baseline VL

Previous ART

VL at time of VF

Observations

1

33

ABC/3TC + DRV/r

81–393

Resuppression without switch (continued on RPV + bDRV)

No drug resistance mutations.

2

159

ETV + DRV/r

67–96

Switch to cART (to include omeprazol).

No genotyping.

3

759

ETV + DRV/r

560–7530

Switch to RPV+ bDRV + DTG

No genotyping.

4

210

ETV + DRV/r

191–131

Resuppression without switch (continued on RPV + bDRV)

No genotyping.

5

< 50

ETV + DRV/r

16,500 (390 five days later)

Poor adherence

No switch (continued on RPV + bDRV)

No genotyping.

6

< 50

ETV + RAL + DRV/r

270–1197

Switch to ETV + DRV/r (post-switch VL of 23 copies)

No drug resistance mutations

7

< 50

ETV + RAL + ATV/r

220–612

Switch to ABC/3TC + DRV/r

No drug resistance mutations

8

95

TDF/FTC + NVP

173,000-1590

Poor adherence

No genotyping

  1. VL: viral load; ART: antiretroviral therapy; VF: virological failure; ABC: abacavir; 3TC:
  2. lamivudine; DRV: darunavir; bDRV: boosted darunavir; ETV: etravirine; RAL: raltegravir; RPV: rilpivirine; TDF: tenofovir; ATV: atazanavir; NVP: nevirapine; DTG:
  3. dolutegravir